Skip to content

Study · In vitro (cell-free) · rat · 1998

1 result

Characterization of vasopressin receptor in rat lung.

Tahara A, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, Yatsu T, Uchida W, Tanaka A

Neuropeptides1 Jun 1998Cited by 10 (Europe PMC)

PMID10189064 (opens in a new tab)DOI10.1016/s0143-4179(98)90049-x (opens in a new tab)PepBankPUB-10189064
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cell-free)Activity measurement

    In rat lung membranes, oxytocin displaced [3H]AVP binding, with the lowest potency among the native neurohypophysial peptides tested.

    In plain wordsIn lab tests on rat lung membranes, oxytocin competed with vasopressin for binding, but less strongly than the other natural peptides tested.

    Peptide
    Oxytocin
    Outcome
    Not applicableDisplacement of [3H]AVP binding by oxytocin in rat lung membranes
    Study

    ratn: not reported in source

    rat lung membranes
    Outcome group
    Receptor activity and mechanism · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Competitive inhibition of [3H]AVP binding showed that neurohypophysial hormones as well as their synthetic analogues displaced [3H]AVP in a concentration-dependent manner. The order of potencies for the native peptides was: AVP > lysine vasopressin = arginine vasotocin > oxytocin.
    1 context sentence
    Summary · context
    This study characterized rat lung membrane arginine vasopressin (AVP) receptors in detail.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:51 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.